アステラス製薬（4503） – Supplementary Documents (FY2021)

Supplementary Documents [IFRS] Financial results for the fiscal year 2021 (FY2021) Astellas Pharma Inc.- FY2021 Financial Results For the year ended March 31, 2022 Three months ended March 31, 2022- Pipeline listCautionary Notes – In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and newproducts effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highlycompetitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.Information about pharmaceutical products (including products currently in development) which is included in this material is not intendedto constitute an advertisement or medical advice.(cid:52)(cid:14)(cid:18)FY20Full YearFY21Full YearChange(%)ForecastsFY21Full YearForecastsFY22Full YearChange fromFY21Change(%) 1,323.0 1,443.011.3%[For the year ended March 31, 2022]1. Consolidated Results (Full Basis)RevenueCost of salesGross profitSG&A expenses XTANDI co-promotion fee in the United states Personnel expenses Advertising and Sales Promotion and OtherR&D expensesAmortisation of intangible assetsGain on divestiture of intangible assetsShare of profit (loss) of investments accounted for using equity method Other income Net foreign exchange gains Fair value remeasurements on contingent considerationOther expense Impairment losses Restructuring costs Net foreign exchange losses Fair value remeasurements on contingent considerationOperating profitUnit: B¥Change 46.66.9 39.744.5 19.19.216.221.5 4.524.20.07.68.21.8-18.6-26.910.3-2.31.019.6 -5.52.611.6 8.13.5 1,249.5246.119.7%1,003.5504.340.4%120.2182.2201.9224.518.0% 23.8 – 0.5 7.6 – 3.6 123.0 101.7 9.3 2.3 6.0 136.110.9%11.62.3145.311.6%24.7120.69.7%181.5 1,296.2253.019.5%1,043.2548.842.3%139.3191.4218.1246.019.0% 28.3 24.2 0.5 15.3 8.2 5.4 104.3 74.9 19.6 – 7.0 155.712.0%6.14.9156.912.1%32.8124.19.6%208.1 Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue Finance incomeFinance expensesProfit before taxIncome tax expenseProfitComprehensive income3.7%2.8%4.0%8.8%15.9%5.0%8.0%9.6%19.0%-2.2%99.7%-49.5%-15.2%-26.4%110.4%-100.0%17.4%14.4%-47.0%112.0%8.0%32.6%2.9% 26.614.7% 541.040.9% 598.041.4%182.0 242.018.3% 254.017.6% 218.016.5% 269.018.6% 216.016.3% 267.018.5% 174.013.1% 208.014.4%9.0%30.6%3.2%72.8%70.2%67.6%(cid:52)(cid:14)(cid:19)2. Consolidated Results (Core Basis)RevenueCost of salesGross profitSG&A expenses XTANDI co-promotion fee in the United states Personnel expenses Advertising and Sales Promotion and OtherR&D expensesGain on divestiture of intangible assetsAmortisation of intangible assetsShare of profit (loss) of investments accounted for using equity methodOperating profitRatio to Revenue Unit: B¥Change 46.66.9 39.744.5 19.19.216.221.5 4.524.20.0-6.6FY20Full YearFY21Full Year 1,249.5246.119.7%1,003.5504.340.4%120.2182.2201.9224.518.0% 23.8 – 0.5251.4 20.1%11.62.3260.620.9%50.7209.916.8% 1,296.2253.019.5%1,043.2548.842.3%139.3191.4218.1246.019.0%28.324.20.5244.718.9%6.14.9245.919.0%55.4190.614.7%Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue -5.52.6-14.7 4.6-19.33.7%2.8%4.0%8.8%15.9%5.0%8.0%9.6%19.0%-2.2%-2.6%-47.0%112.0%-5.6%9.1%-9.2%Finance incomeFinance expensesProfit before taxIncome tax expenseProfit 3. Exchange RateChange(%)ForecastsFY21Full YearForecastsFY22Full YearChange fromFY21Change(%) 1,323.0 1,443.011.3% 541.040.9% 598.041.4%182.0 242.018.3% 254.017.6%9.0%30.6%3.2% 270.020.4% 290.020.1%18.5% 213.016.1% 223.015.5%17.0%USD/YenEUR/Yen* Fx impacts: Revenue +59.6 billion yen and Core operating profit +18.5 billion yen * Fx impact on elimination of unrealized gain: COGs ratio +0.2ppt FY20Ave.FY21Ave.FY20End106124 112131 111130 122135Unit: yenFY21EndForecastsFY21Full Year 110130ForecastsFY22Full Year 120135(cid:52)(cid:14)(cid:20)4. Reconciliation of Full Basis to Core BasisRevenueCost of salesGross profitSG&A expensesR&D expensesAmortisation of intangible assetsGain on divestiture of intangible assetsShare of profit (loss) of investments accountedfor using equity methodOther income *Other expenses *Operating profitFinance incomeFinance expensesProfit before taxIncome tax expenseProfitFull basis 1,249.5246.11,003.5504.3224.523.8 – FY20Full yearAdjustment- – – – – – – – Core basisFull basis 1,249.5246.11,003.5504.3224.523.8 – 1,296.2253.01,043.2548.8246.028.3 24.2 -7.6 -123.0 115.3 – – 115.326.0 89.30.5 – – 251.4 11.62.3 260.650.7 209.90.5 7.6 123.0136.1 11.62.3 145.324.7 120.60.5 15.3 104.3155.76.1 4.9 156.932.8 124.1FY21Full yearAdjustment- – – – – – – – -15.3 -104.3 89.1 – – 89.1 22.6 66.5Unit: B¥Core basis 1,296.2253.01,043.2548.8246.028.3 24.20.5 – – 244.76.1 4.9 245.955.4 190.6 * “Other income” and “Other expenses” are excluded from Core basis results.”Other income” and “Other expenses” include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.(cid:52)(cid:14)(cid:21)5. Revenue by RegionRevenueJapanUnited StatesFY20Full Year FY21Full Year Unit: B¥Change 46.6-20.4Change(%)3.7%-7.3% 64.313.6%Established Markets 22.07.5%Ratio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueRatio to Revenue1,249.5279.122.3%473.237.9%293.223.5%59.34.7%111.18.9%33.62.7%1,296.2258.820.0%537.541.5%315.224.3%66.35.1%110.18.5%8.40.6%Greater China 7.011.8% International Markets -1.0-0.9% Others -25.2-75.0% -28.1%ForecastsFY21Full Year 1,323.0252.119.0%552.541.8%322.124.3%65.04.9%122.59.3%8.90.7%Change fromFY21Change(%)11.3%0.5%19.9%7.8%12.2%7.7%ForecastsFY22Full Year 1,443.0260.018.0%644.244.6%339.923.6%74.45.2%118.58.2%6.00.4%- Established Markets: Europe, Canada, Australia- Greater China: China, Hong Kong, Taiwan- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc6. Per Share InformationThe number of shares issued (thousand) Treasury Shares (thousand) The number of shares issued after deducting Treasury Shares (thousand)Earnings per share (yen)Earnings per share (yen) core basisDividend per share (yen)Return on Equity (%)Dividend on Earnings (%)FY20Full YearFY21Full Year 1,861,7878,7581,853,02964.93113.03429.0%5.8% 1,835,8528,7781,827,07467.08103.03508.7%6.5%ForecastsFY21Full YearForecastsFY22Full Year 93.90114.9550 113.84122.05607. Investment in Property, Plant and Equipment　Depreciation/AmortisationInvestment in Property , Plant and EquipmentDepreciation (PP&E)ConsolidatedConsolidatedConsolidatedAmortisation of Intangible Assets (incl. software, etc.)- Investment in Property , Plant and Equipment does not include right-of-use assetFY20Full YearFY21Full YearUnit: B¥ChangeChange(%)ForecastsFY21Full YearForecastsFY22Full YearChange fromFY21Change(%) 33.7 30.2 -3.5-10.5% 34.0 39.029.3% 40.0 40.1 0.1 42.0 40.0 32.7 39.6 7.0 38.0 42.00.2%21.3%-0.1%6.0%(cid:52)(cid:14)(cid:22)8. Sales of major products1) GlobalXTANDIXOSPATAPADCEVEVRENZOPrografUnited Statesex-US Japan Established Markets Greater China International MarketsJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsJapanUnited StatesEstablished MarketsJapanEstablished MarketsJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsBetanis/Myrabetriq/BETMIGAJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsVesicareFY20Full Year 458.4 238.6 219.8 40.2 149.3 4.9 25.5 23.8 3.8 15.5 4.4 0.0 0.2 12.8 – 12.8 – 1.1 1.1 – 163.6 35.1 88.0 29.9 2.2 8.5 31.6 18.5 2.2 6.2 1.0 3.7 182.7 40.7 11.8 64.2 34.2 31.7FY21Full Year 534.3276.9257.447.2170.17.932.234.13.918.99.01.50.721.71.819.50.52.62.50.1172.337.587.236.72.98.122.010.01.75.51.03.7185.438.29.467.938.131.7Unit: B¥Change 75.938.337.67.020.83.06.710.20.13.44.71.50.58.91.86.70.51.51.40.18.72.4-0.86.80.7-0.4-9.7-8.5-0.5-0.70.0-0.02.7-2.5-2.43.73.90.0Change(%)16.6%16.1%17.1%17.3%13.9%62.0%26.5%42.9%3.2%21.9%105.8%-348.5%69.5%-52.2%-131.5%121.8%-5.3%6.9%-0.9%22.7%33.4%-5.0%-30.6%-45.9%-23.9%-11.9%1.0%-0.2%1.5%-6.2%-20.6%5.8%11.5%0.1%ForecastsFY21Full Year 554.1290.2264.047.1176.08.232.635.44.419.29.41.70.620.70.819.70.27.24.13.2176.336.793.035.72.78.218.97.61.55.21.03.6185.738.29.167.337.933.2ForecastsFY22Full Year 642.5353.9288.652.6182.113.340.646.24.925.211.82.41.936.54.327.64.69.96.33.4178.736.290.240.63.68.112.71.81.34.81.03.9190.735.710.469.941.333.5Change fromFY21Change(%)20.3%27.8%12.1%11.4%7.1%67.5%26.1%35.5%26.0%33.4%30.6%54.0%173.5%68.0%146.7%41.4%891.8%281.2%152.6%-3.7%-3.5%3.5%10.9%21.8%0.0%-42.0%-82.4%-20.2%-13.3%-5.8%5.1%2.9%-6.6%10.4%2.9%8.3%5.4%- Sales of products in Japan are shown in a gross sales basis- Established Markets: Europe, Canada, Australia- Greater China: China, Hong Kong, Taiwan- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.- PADCEV (United States): Co-promotion revenue from Seagen- Astellas’ EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.(cid:52)(cid:14)(cid:23)2）Revenue by region(1) JapanXTANDIXOSPATAPADCEVEVRENZOBetanisVesicarePrograf (Including Graceptor)HarnalFunguard

Suglat [Family] SujanuRepathaLinzessBLINCYTOEVENITYSmyrafGeninaxVaccinesGonaxCimziaMysleeTotal Rx Sales In Japanese market- Sales of products in Japan are shown in a gross sales basis.FY20Full YearFY21Full YearUnit: B¥ChangeChange(%)ForecastsFY21Full YearForecastsFY22Full YearChange fromFY21Change(%) 40.23.8 – 1.1 35.1 18.540.7 3.0 4.4 27.9 11.3 5.1 6.4 4.5 24.8 1.7 2.5 7.9 5.1 10.07.8 276.6 47.23.9 1.8 2.5 37.5 10.038.2 2.6 1.6 30.3 12.5 5.8 6.9 6.4 31.4 2.4 2.6 5.1 5.0 11.2 7.0 256.97.0 0.1 1.8 1.4 2.4 -8.5 -2.5 -0.4 -2.8 2.4 1.1 0.7 0.5 1.8 6.6 0.7 0.1 -2.8 -0.1 1.1 -0.8 -19.617.3%3.2%-121.8%6.9%-45.9%-6.2%-14.0%-63.0%8.4%10.1%12.8%8.6%40.1%26.6%42.5%3.7%-35.1%-1.4%11.2%-10.1%-7.1% 47.14.4 0.8 4.1 36.7 7.6 38.2 2.4 1.5 30.57.0 3.1 3.1 5.2 5.0 33.19.3% 52.64.9 4.3 6.3 36.2 1.8 35.7 1.4 0.9 7.8 3.3 8.6 4.9 5.5 257.511.5%26.0%146.7%152.6%-3.5%-82.4%-6.6%-45.3%-46.6%12.8%39.1%67.7%-1.3%-22.3%0.2% 6.9 250.3 (cid:52)(cid:14)(cid:24)　(2) United StatesRevenueXTANDIXOSPATAPADCEVMyrbetriqVesicarePrografMYCAMINEAmBisomeCRESEMBALexiscanXTANDIXOSPATAPADCEVEVRENZO BETMIGA Vesicare Prograf Omnic MYCAMINE　(3) Established MarketsRevenue- Established Markets: Europe, Canada, AustraliaFY20Full Year 4,4622,2501461218292011283114160623FY21Full Year 4,7822,464168174775158448135194725FY20Full Year 2,370 1,207 36 – – 241 50 519 65 45FY21Full Year 2,414 1,303 69 4 1 281 42 520 67 22Unit: M$Change 3202142253-54-6-28-352135103Unit: M€Change 44 96 34 4 1 39 -8 1 2 -23Change(%)7.2%9.5%15.1%43.7%-6.5%-28.2%-25.1%-41.9%18.5%21.8%16.5%1.9%8.0%95.0%–16.3%-16.5%0.3%3.6%-51.6%Change(%)ForecastsFY21Full Year 5,0222,638175179845138345127185732ForecastsFY21Full Year 2,477 1,354 73 1 24 275 40 518 65 23ForecastsFY22Full Year 5,3682,949210230752118718143209739ForecastsFY22Full Year 2,5171,349883425301355186415Change fromFY21Change(%)12.3%19.7%24.9%32.4%-3.1%-25.3%3.4%-62.5%6.2%7.4%1.9%4.3%3.5%26.3%859.1%-7.2%-16.1%-0.4%-5.2%-29.0%Change fromFY21Change(%)(cid:52)(cid:14)(cid:25)　(4) Greater ChinaRevenue- Greater China: China, Hong Kong, Taiwan　(5) International MarketsRevenueXTANDIXOSPATA BETMIGA Vesicare Prograf Harnal MYCAMINE FeburicXTANDIXOSPATA BETMIGA Vesicare Prograf Harnal MYCAMINEFY20Full Year 59.34.90.02.21.034.210.82.52.6FY21Full Year 66.37.91.52.91.038.18.22.92.9FY20Full Year 111.125.50.28.53.731.715.14.4FY21Full Year 110.132.20.78.13.731.716.16.1Unit: B¥Change 7.03.01.50.70.03.9-2.60.40.3Unit: B¥Change -1.06.70.5-0.4-0.00.01.11.8Change(%)11.8%62.0%-33.4%1.0%11.5%-24.4%17.9%9.7%Change(%)-0.9%26.5%348.5%-5.0%-0.2%0.1%7.1%40.4%ForecastsFY21Full Year 65.08.21.72.71.037.97.92.22.7ForecastsFY21Full Year 122.532.60.68.23.633.216.26.1ForecastsFY22Full Year 74.413.32.43.61.041.38.01.42.8ForecastsFY22Full Year 118.540.61.98.13.933.517.86.2Change fromFY21Change(%)12.2%67.5%54.0%21.8%-5.8%8.3%-2.3%-53.4%-2.5%7.7%26.1%173.5%0.0%5.1%5.4%10.3%1.1%Change fromFY21Change(%)- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc(cid:52)(cid:14)(cid:26)9. Consolidated statements of financial positionAssetsNon-current assetsProperty, plant and equipmentGoodwillIntangible assetsTrade and other receivablesInvestments accounted for using equity methodCurrent assetsDeferred tax assetsOther financial assetsOther non-current assetsInventoriesTrade and other receivablesIncome tax receivableOther financial assetsOther current assetsCash and cash equivalentsEquity and LiabilitiesEquityEquity attributable to owners of the parentShare capitalCapital surplusTreasury sharesRetained earningsOther components of equityLiabilitiesNon-current liabilitiesTrade and other payablesDeferred tax liabilitiesRetirement benefit liabilitiesProvisionsOther financial liabilitiesOther non-current liabilitiesCurrent liabilitiesTrade and other payablesIncome tax payableProvisionsOther financial liabilitiesOther current liabilitiesFY20End FY21End 2,273.61,401.0264.6284.0651.433.9 7.1 54.2 95.99.9 872.6164.1343.2 14.05.6 19.7 326.12,332.41,409.0269.0303.0623.429.8 10.0 72.3 91.89.5 923.4153.1382.5 21.521.3 29.0 316.0 FY20EndFY21End 2,273.61,386.11,386.1103.0177.8-15.4 953.3 167.4 2,332.41,460.31,460.3103.0179.5-13.9 944.3 247.5 887.5295.10.4 18.239.0 5.8 199.032.8 592.4124.88.4 22.2 148.2288.9 872.1184.70.7 5.8 37.2 5.8 95.9 39.2 687.4130.732.4 16.6 185.0322.8Unit: B¥ChangeUnit: B¥Change58.8 8.0 4.4 19.0 -28.0-4.1 2.9 18.2 -4.0 -0.4 50.8 -11.0 39.3 7.6 15.7 9.3 -10.158.8 74.2 74.2- 1.6 1.4 -9.0 80.1-15.4 -110.5 0.3 -12.3-1.8 0.0 -103.1 6.5 95.06.0 24.0 -5.6 36.8 33.9(cid:52)(cid:14)(cid:18)(cid:17)10. Employees Total11. ShareholdersFY20EndNumber of employeesFY21End 15,455 14,522FY20EndFY21EndBanksSecuritiesOther companiesForeign companiesIndividuals and othersTreasury Stock** Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust and ESOP (Employee Stock Ownership Plan) trust. 38.3%4.3%3.1%45.6%8.6%0.1%38.4%4.6%3.2%45.5%8.2%0.0%(cid:52)(cid:14)(cid:18)(cid:18)Change(%)FY21Change(%)Change(%)Change(%)[For the year ended March 31, 2021]1. Consolidated Results (Full Basis)RevenueCost of salesGross profitSG&A expenses XTANDI co-promotion fee in the United states Personnel expenses Advertising and Sales Promotion and OtherR&D expensesAmortisation of intangible assetsGain on divestiture of intangible assetsShare of profit (loss) of investments accounted for using equity method Other income Net foreign exchange gains Fair value remeasurements on contingent considerationOther expense Impairment losses Restructuring costs Net foreign exchange losses Fair value remeasurements on contingent considerationOperating profitFinance incomeFinance expensesProfit before taxIncome tax expenseProfitComprehensive incomeAPR.-JUN.(Quarterly) 326.162.219.1%263.9137.142.0%34.549.053.658.317.9% 6.0 – 0.3 0.4 0.3 – 27.1 26.1 0.6 – 0.0 36.111.1%1.51.735.811.0%5.130.79.4%36.2 Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue JUL.-SEP.(Quarterly) 325.562.519.2%263.0133.441.0%36.647.049.860.718.7% 6.4 – 0.0 2.4 2.0 0.0 10.8 0.0 2.0 – 8.7 54.116.6%0.41.353.316.4%12.340.912.6%33.9 6.2%4.3%6.7%13.5%9.4%7.3%23.0%1.8%1.8%—82.0%-70.5%-465.2%690.7%—91.4%-40.7%284.3%79.6%-40.5%-47.7%-39.1%-34.7%OCT.-DEC.(Quarterly) 340.669.420.4%271.3135.939.9%37.647.051.358.617.2% 7.9 24.1 1.7 3.1 – 2.2 18.6 0.7 15.8 1.7 0.0 79.223.3%0.41.378.323.0%17.460.917.9%94.5 5.5%4.4%5.8%9.9%24.8%5.5%4.9%11.6%12.7%—24.6%–99.9%-75.4%-100.0%116.7%-100.0%109.5%107.5%-85.9%363.6%84.6%91.9%82.5%49.4%Unit: B¥ JAN.-MAR.(Quarterly) 303.958.9 19.4%245.0142.446.9%30.648.463.468.422.5% 8.0 0.1 -1.5 12.7 7.6 4.8 51.1 48.1 1.3 – – -13.7-4.5%3.80.7-10.5-3.5%-2.1-8.4-2.8%43.6 4.7%1.7%5.5%12.4%28.0%7.8%7.0%2.6%37.0%—20.8%-100.0%-292.3%-68.5%713.6%–92.6%9.1%-86.4%150.7%4.2%15.8%1.3%21.4%-1.5%1.0%-2.1%0.8%2.3%0.0%0.7%22.8%24.2%–369.6%309.5%–30.7%-26.0%-80.5%–100.0%–24.7%14.6%—70.2%(cid:52)(cid:14)(cid:18)(cid:19)2. Consolidated Results (Core Basis) XTANDI co-promotion fee in the United states Personnel expenses Advertising and Sales Promotion and OtherR&D expensesAmortisation of intangible assetsGain on divestiture of intangible assetsShare of profit (loss) of investments accounted for using equity methodOperating profitRatio to Revenue RevenueCost of salesGross profitSG&A expensesFinance incomeFinance expensesProfit before TaxIncome tax expenseProfit Change(%)FY21Change(%)OCT.-DEC.(Quarterly)Change(%)Change(%)APR.-JUN.(Quarterly) 326.162.219.1%263.9137.142.0%34.549.053.658.317.9% 6.0 – 0.362.8 19.3%1.51.762.619.2%13.349.215.1% Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue JUL.-SEP.(Quarterly) 325.562.519.2%263.0133.441.0%36.647.049.860.718.7% 6.4 – 0.062.5 19.2%0.41.361.718.9%12.149.515.2% 6.2%4.3%6.7%13.5%9.4%7.3%23.0%1.8%1.8%—0.9%284.3%79.6%-0.4%23.3%-5.3%5.5%4.4% 5.8%9.9% 24.8%5.5%4.9%11.6% 12.7%—6.6% -85.9%363.6%-11.6% -21.9%-8.6% 340.669.420.4%271.3135.939.9%37.647.051.358.617.2%7.924.11.794.827.8%0.41.393.927.6%22.970.920.8%Unit: B¥ JAN.-MAR.(Quarterly) 303.958.9 19.4%245.0142.446.9%30.648.463.468.422.5%8.00.1-1.524.78.1%3.80.727.99.2%7.020.96.9% 4.7%1.7%5.5%12.4%28.0%7.8%7.0%2.6%37.0%–29.0%-86.4%150.7%23.5%47.8%17.3%-1.5%1.0%-2.1%0.8%2.3%0.0%0.7%22.8%24.2%—48.1%-24.7%14.6%-46.6%-21.6%-51.7%(cid:52)(cid:14)(cid:18)(cid:20)3. Revenue by RegionRevenueAPR.-JUN.(Quarterly) Change(%)6.2%-13.2%JUL.-SEP.(Quarterly) FY21Change(%)5.5%-5.2%OCT.-DEC.(Quarterly) Change(%) 14.1% 14.1% JapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsOthersRatio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueRatio to Revenue326.167.5 20.7%133.641.0%78.0 23.9%16.4 5.0%27.8 8.5%2.8 0.9%21.8%15.5%-8.1%-21.9%325.563.0 19.4%136.541.9%79.4 24.4%16.6 5.1%27.5 8.4%2.5 0.8%Unit: B¥ JAN.-MAR.(Quarterly) 303.955.5 18.3%129.542.6%75.925.0%16.05.3%27.18.9%-0.2 -0.1% 4.7%-6.3%15.7%3.5%21.2%-10.3%-28.1%Change(%)-1.5%-3.1%10.3%1.0%3.2%15.3%-101.1%340.672.7 21.3%137.840.5%81.9 24.0%17.3 5.1%27.7 8.1%3.3 1.0%- Established Markets: Europe, Canada, Australia- Greater China: China, Hong Kong, Taiwan- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.4. Investment in Property , Plant and EquipmentDepreciation/AmortisationAPR.-JUN.(Quarterly)Change(%)JUL.-SEP.(Quarterly)Change(%)OCT.-DEC.(Quarterly)Change(%)JAN.-MAR.(Quarterly)Change(%)Unit: B¥Investment in Property , Plant and EquipmentDepreciation (PP&E)ConsolidatedConsolidatedConsolidatedAmortisation of Intangible Assets (incl. software, etc.)- Investment in Property , Plant and Equipment does not include right-of-use asset.5.2 9.9 8.2 -27.3%-0.6%2.6%7.8 10.09.0 9.3 10.4 11.10.3%3.5%7.8 9.7 -20.4%-2.1%37.4% 11.431.6%6.0%8.3%3.7%-55.9%FY214.9%-0.1%12.7%(cid:52)(cid:14)(cid:18)(cid:21)5. Sales of major products1) GlobalXTANDIXOSPATAPADCEVEVRENZOPrografUnited Statesex-US Japan Established Markets Greater China International MarketsJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsJapanUnited StatesEstablished MarketsJapanEstablished MarketsJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsBetanis/Myrabetriq/BETMIGAJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsVesicareChange(%)FY21Change(%)Change(%)Change(%)APR.-JUN.(Quarterly) 132.9 68.4 64.5 12.0 42.8 1.9 7.8 8.3 1.1 4.6 2.0 0.5 0.1 4.2 – 4.2 – 0.6 0.6 – 44.0 9.8 22.8 8.5 0.7 2.2 7.4 4.6 0.2 1.4 0.3 0.9 45.2 10.2 2.1 16.2 9.6 7.0JUL.-SEP.(Quarterly) 134.7 72.7 62.0 11.5 41.1 1.7 7.6 8.2 1.0 4.4 2.1 0.5 0.1 4.9 – 4.9 – 0.8 0.7 0.1 40.4 8.9 19.3 9.4 0.6 2.3 5.4 2.0 0.7 1.5 0.2 1.0 47.1 9.4 2.7 18.2 9.9 6.918.7%9.1%31.0%18.5%36.1%165.1%12.2%47.7%6.6%26.9%99.4%–41.9%-41.9%-282.9%282.9%-8.8%16.2%-0.5%29.4%56.9%5.8%-4.4%-7.7%-39.4%14.4%22.3%-3.9%-0.3%-7.9%-40.8%17.0%22.9%-21.7%OCT.-DEC.(Quarterly) 143.974.669.312.944.91.99.69.21.05.42.40.30.15.60.55.00.00.70.70.042.510.519.99.70.71.85.22.10.51.20.31.148.810.72.817.510.37.618.6%24.5%12.4%17.9%9.9%11.1%18.8%53.0%19.0%21.1%156.3%-785.7%60.8%-60.8%-352.1%288.3%-2.2%8.5%-8.9%21.0%23.5%15.3%-36.6%-55.3%-46.3%-6.6%-10.2%6.0%6.4%-5.3%-11.7%9.9%17.7%8.9%Unit: B¥JAN.-MAR.(Quarterly) 122.7 61.2 61.6 10.7 41.3 2.4 7.2 8.3 0.8 4.5 2.5 0.2 0.3 7.0 1.2 5.4 0.4 0.5 0.5 0.0 45.4 8.3 25.2 9.0 0.9 1.9 4.2 1.4 0.2 1.3 0.3 0.8 44.3 7.9 1.8 16.0 8.3 10.222.8%26.6%18.9%16.6%12.4%97.9%52.9%38.4%-3.5%25.8%81.8%-321.1%68.1%-50.8%-91.3%88.2%-0.5%4.8%-9.1%27.9%15.0%-21.7%-38.8%-59.9%67.6%-29.0%-0.4%8.4%0.2%-3.5%-1.7%1.8%20.1%-16.4%6.1%4.5%7.7%16.3%1.9%45.7%23.4%34.5%-7.8%14.0%102.7%822.1%176.8%102.2%-54.9%-16.2%19.7%-9.9%-1.4%14.4%13.9%44.0%-15.8%-39.4%-64.9%-5.2%-19.5%-5.1%-12.4%-0.2%-8.6%-24.3%-3.5%-11.5%39.7%- Sales of products in Japan are shown in a gross sales basis- Established Markets: Europe, Canada, Australia- Greater China: China, Hong Kong, Taiwan- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc. – PADCEV (United States): Co-promotion revenue from Seagen- Astellas’ EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc. (cid:52)(cid:14)(cid:18)(cid:22)2）Revenue by region(1) JapanXTANDIXOSPATAPADCEVEVRENZOBetanisVesicarePrograf (Including Graceptor)HarnalFunguard

Suglat [Family］ SujanuRepathaLinzessBLINCYTOEVENITYSmyrafGeninaxVaccinesGonaxCimziaMysleeTotal Rx Sales In Japanese market- Sales of products in Japan are shown in a gross sales basis.APR.-JUN.(Quarterly)Change(%)JUL.-SEP.(Quarterly)Change(%)OCT.-DEC.(Quarterly)Change(%)Change(%)FY2117.9%19.0%-288.3%8.5%-55.3%-5.3%-15.1%-68.3%11.8%15.2%9.8%11.7%52.2%28.8%52.3%19.3%-29.0%3.4%14.1%-10.7%-5.3%11.5 1.0 – 0.7 8.9 2.0 9.4 0.6 0.4 7.5 3.1 1.4 1.7 1.5 7.4 0.6 0.6 2.0 1.3 2.8 1.8 62.612.9 1.0 0.5 0.7 10.5 2.1 10.7 0.7 0.5 8.3 3.4 1.6 2.0 1.8 8.8 0.7 0.8 3.2 1.3 3.1 1.9 72.0Unit: B¥JAN.-MAR.(Quarterly)10.7 0.8 1.2 0.5 8.3 1.4 7.9 0.5 0.3 6.6 2.7 1.3 1.5 1.6 8.1 0.5 0.5 -0.1 1.1 2.4 1.5 55.2 16.6%-3.5%-88.2%4.8%-59.9%-3.5%-10.6%-58.0%7.1%6.5%9.5%7.9%50.0%39.2%22.2%-11.1%-36.5%20.8%12.1%-9.9%-5.9%16.3%-7.8%-19.7%-1.4%-64.9%-8.6%-8.6%-32.0%3.8%5.1%8.1%1.7%41.8%40.7%-5.5%0.1%-238.2%-1.6%5.8%-8.0%-3.0%12.0 1.1 – 0.6 9.8 4.6 10.2 0.7 0.4 7.9 3.2 1.5 1.8 1.4 7.0 0.6 0.7 0.01.3 2.8 1.8 67.018.5%6.6%-282.9%16.2%-7.7%-7.9%-20.2%-70.7%10.9%13.6%25.3%12.9%17.6%1.6%179.6%15.4%0.0%-20.3%12.3%-11.4%-12.9%(cid:52)(cid:14)(cid:18)(cid:23)　(2) United StatesRevenueXTANDIXOSPATAPADCEVMyrbetriqVesicarePrografMYCAMINEAmbisomeCRESEMBA LexiscanXTANDIXOSPATAPADCEVEVRENZO BETMIGA Vesicare Prograf Omnic MYCAMINE　(3) Established MarketsRevenue- Established Markets: Europe, Canada, AustraliaAPR.-JUN.(Quarterly) 1,221 625 42 38 208 2 19 14 30 45 196Change(%)JUL.-SEP.(Quarterly) 1,240 661 40 45 175 6 24 16 38 49 18612.1%7.2%24.7%39.5%-2.2%-40.4%-41.8%-40.4%35.9%25.8%77.1%APR.-JUN.(Quarterly) 591 325 15 – – 65 11 123 17 7Change(%)JUL.-SEP.(Quarterly) 612 317 16 – 1 72 12 140 19 69.4%22.2%79.0%–16.2%2.7%5.1%12.2%-47.6%FY21Change(%)OCT.-DEC.(Quarterly) 1,211 656 48 44 174 5 25 11 33 48 16910.2%20.1%16.9%55.3%-12.2%-47.9%-14.9%-25.8%29.3%23.5%3.1%FY21Change(%)OCT.-DEC.(Quarterly) 629 345 18 0 075 9 134 16 51.2%4.9%146.7%–15.4%-11.1%4.8%12.1%-47.7%Change(%)Change(%)Unit: M$JAN.-MAR.(Quarterly) 1,110 522 39 46 218 2 16 7 33 52 174Unit: M€JAN.-MAR.(Quarterly) 582 316 19 3 0 69 10 123 16 46.3%16.4%16.3%39.0%-16.7%50.9%-9.6%-38.3%-2.3%8.4%2.3%-1.1%7.4%73.2%–22.4%-32.1%-2.7%-9.6%-54.9%0.2%-5.6%3.4%41.5%4.8%-17.0%-32.1%-65.9%18.1%31.6%4.7%-1.1%-0.5%97.5%–11.3%-21.2%-5.6%1.5%-58.1%Change(%)Change(%)(cid:52)(cid:14)(cid:18)(cid:24)　 (4) Greater ChinaRevenue- Greater China: China, Hong Kong, Taiwan　(5) International MarketsRevenueXTANDIXOSPATA BETMIGA Vesicare Prograf Harnal MYCAMINE FeburicXTANDIXOSPATABETMIGAVesicarePrografHarnalMYCAMINEAPR.-JUN.(Quarterly) 16.41.90.50.70.39.62.00.60.6Change(%)JUL.-SEP.(Quarterly) 16.61.70.50.60.29.92.00.70.715.5%165.1%-56.9%22.3%22.9%-46.8%25.3%9.7%APR.-JUN.(Quarterly) 27.87.80.12.20.97.04.31.6Change(%)JUL.-SEP.(Quarterly) 27.57.60.12.31.06.93.82.0-8.1%12.2%-5.8%-3.9%-21.7%2.1%64.6%FY21Change(%)OCT.-DEC.(Quarterly) 17.31.90.30.70.310.32.10.80.78.3%11.1%-23.5%-10.2%17.7%-33.4%1.7%15.0%FY21Change(%)OCT.-DEC.(Quarterly) 27.79.60.11.81.17.64.61.13.7%18.8%785.7%15.3%6.0%8.9%-2.4%97.2%Unit: B¥JAN.-MAR.(Quarterly) 16.0 2.4 0.2 0.9 0.3 8.3 2.1 0.8 0.8Unit: B¥JAN.-MAR.(Quarterly) 27.1 7.2 0.3 1.9 0.8 10.2 3.4 1.4Change(%)21.2%97.9%-15.0%-0.4%20.1%-3.6%28.2%-0.4%Change(%)-10.3%52.9%321.1%-21.7%8.4%-16.4%30.4%-5.0%Change(%)3.2%45.7%822.1%44.0%-5.1%-11.5%9.0%20.0%15.6%Change(%)15.3%23.4%176.8%-15.8%-12.4%39.7%0.2%16.4%- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.(cid:52)(cid:14)(cid:18)(cid:25)R&D Pipeline The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.As of Apr 2022Underlined items indicate changes from the previous announcement in Feb 2022.XTANDI and Strategic products (1/2)Generic nameCode No.(Brand name)enzalutamideMDV3100(XTANDI)gilteritinibASP2215(XOSPATA)Modality / TechnologyClassificationTarget diseasePhase *Licensor **RemarksSmall moleculeAndrogen receptor inhibitorMetastatic castration-sensitive prostate cancerChinaP-IIIPfizerSmall molecule FLT3 inhibitorPost-chemotherapy maintenanceacute myeloid leukemiaIn-houseenfortumab vedotinASG-22ME(PADCEV)Antibody-drug conjugate(ADC)Nectin-4 targeted ADCMetastatic urothelial cancer, platinum-containingchemotherapy and PD-1/L1 inhibitor pretreatedEuropeApproved (Apr 2022)In-house[Co-development withSeagen]Non-metastatic castration-sensitive prostate cancerP-IIIPost-hematopoietic stem cell transplant maintenanceacute myeloid leukemiaP-IIINewly diagnosed acute myeloid leukemiawith high intensity induction of chemotherapyNewly diagnosed acute myeloid leukemiawith low intensity induction of chemotherapyAcute myeloid leukemia in pediatric patientsP-IIIMetastatic urothelial cancer, previously untreated(first line; combo with pembrolizumab)Muscle-invasive bladder cancer(combo with pembrolizumab)Other solid tumorsNon-muscle-invasive bladder cancerP-IIIP-IIIP-IP-IIIP-IIIP-IIP-I(cid:52)(cid:14)(cid:18)(cid:26)XTANDI and Strategic products (2/2)Generic nameCode No.(Brand name)zolbetuximabIMAB362roxadustatASP1517/FG-4592(EVRENZO)fezolinetantESN364Modality / TechnologyClassificationTarget diseasePhase *Licensor **RemarksAntibodyAnti-Claudin 18.2monoclonal antibodyGastric and gastroesophageal junctionadenocarcinomaIn-house(Ganymed)Small moleculeHIF-PH inhibitorChemotherapy-induced anemiaFibroGenPancreatic adenocarcinomaP-IIIP-IIP-IISmall moleculeNK3 receptor antagonistVasomotor symptoms associated with menopauseP-IIIresamirigene bilparvovecAT132Gene therapy(AAV-based genetherapy)MTM1 gene replacement toexpress myotubularinX-linked myotubular myopathyP-II* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.** Compounds with “In-house” in this column include ones discovered by collaborative research.Updates from the previous announcement (Feb 2022):enfortumab vedotin (ASG-22ME): Obtained the approval in Europe in Apr 2022 for locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor.Astellas has rights inJapan, Europe, theCommonwealth ofIndependent States,the Middle East, andSouth AfricaIn-house(Ogeda)In-house(AudentesTherapeutics)(cid:52)(cid:14)(cid:19)(cid:17)Modality / TechnologyClassificationTarget diseasePhase *Licensor **RemarksProjects with Focus Area approach (1/2)Generic nameCode No.(Brand name)PrimaryFocusImmuno-oncologyASP9801Oncolytic virusOncolytic virus carryingIL-7 and IL-12CancerASP7517Cell therapy (artificialadjuvant vector cells)WT1 loadedartificial adjuvant vector cellAcute myeloid leukemia andmyelodysplastic syndromeSolid tumorASP0739Cell therapy (artificialadjuvant vector cells)NY-ESO-1 loadedartificial adjuvant vector cellCancerASP1570Small moleculeDGKζ inhibitorCancerASP2138AntibodyAnti-Claudin 18.2 and anti-CD3bispecific antibodyGastric and gastroesophageal junctionadenocarcinoma, pancreatic adenocarcinomaASP7317BlindnessandRegenerationMitochondriaBiologybocidelparASP0367/MA-0211Cell therapyRetinal pigment epithelium cells Geographic atrophy secondary to age-related macularP-Idegeneration, Stargardt diseaseSmall moleculePPARδ modulatorPrimary mitochondrial myopathiesDuchenne muscular dystrophyASP8731/ML-0207Small moleculeBACH1 inhibitorSickle cell diseaseP-IP-IIP-IP-IP-IP-IP-IIP-IP-ITottori University[Discovered throughcollaborativeresearch]RIKEN[Discovered throughcollaborativeresearch]RIKEN[Discovered throughcollaborativeresearch]In-houseXencor[Discovered throughcollaborativeresearch]In-house(Ocata Therapeutics)In-house(Mitobridge)In-house(Mitobridge)(cid:52)(cid:14)(cid:19)(cid:18)Modality / TechnologyClassificationTarget diseasePhase *Licensor **RemarksProjects with Focus Area approach (2/2)PrimaryFocusGeneticregulationGeneric nameCode No.(Brand name)resamirigenebilparvovecAT132 ***AT845FX-322(Otherprojects withFocus Areaapproach)Gene therapy(AAV-based genetherapy)Gene therapy(AAV-based genetherapy)Small moleculeMTM1 gene replacement toexpress myotubularinX-linked myotubular myopathyGAA gene replacement toexpress GAA enzymePompe diseaseSensorineural hearing lossInner ear progenitor cellactivator(combination of GSK-3 inhibitorand HDAC inhibitor)Recombinant human heparin-binding epidermal growth factor-like growth factorASP0598Recombinant proteinChronic tympanic membrane perforationAuration BiotechASP3082Small moleculeCancerIn-house* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.** Compounds with “In-house” in this column include ones discovered by collaborative research.*** AT132 is also listed in “XTANDI and Strategic products”.Updates from the previous announcement (Feb 2022):ASP8731/ML-0207: Entered into Phase 1 for sickle cell disease.ASP3082: Entered into Phase 1 for cancer.ASP1951/PTZ-522: Discontinued Phase 1 program for cancer.ASP1128/MA-0217: Discontinued the development for acute kidney injury because Phase 2 study did not meet its primary endpoint.ASP3772: Discontinued the development for prevention of pneumococcal disease in Phase 2 due to strategic prioritization.ASP2390: Discontinued Phase 1 program for house dust mite-induced allergic rhinitis.In-house(AudentesTherapeutics)In-house(AudentesTherapeutics)FrequencyTherapeuticsAstellas has rights inEx-US marketsP-IIP-IP-IIP-IP-I(cid:52)(cid:14)(cid:19)(cid:19)OthersmirabegronYM178Generic nameCode No.(Brand name)peficitinibASP015KModality / TechnologyClassificationTarget diseasePhase *Licensor **RemarksSmall moleculeβ3 receptor agonistNeurogenic detrusor overactivity in pediatric patientsEuropeP-IIIIn-houseSmall moleculeJAK inhibitorRheumatoid arthritisChinaP-IIIIn-houseOveractive bladder in pediatric patientsEuropeP-IIIisavuconazoleSmall moleculeAzole antifungalInvasive aspergillosis and mucormycosisin pediatric patientsUSP-IIBasileaASP8062Small moleculeGABAB receptor positiveallosteric modulatorOpioid use disorderIn-houseAlcohol use disorderP-IIP-I* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.** Compounds with “In-house” in this column include ones discovered by collaborative research.(cid:52)(cid:14)(cid:19)(cid:20)Rx+ ProgramSphere(Business area)ProgramChronicdiseaseprogressionpreventionAs of Apr 2022Underlined items indicate changes from the previous announcement in Feb 2022.Game applicationfor exercise supportSmartphone application to support exercise using motion sensing technology for peoplewho needs regular exerciseUnder developmentBANDAI NAMCOEntertainmentConceptStatus *PartnerRemarksFit-eNceService to provide scientifically evidenced exercise programs and systems supporting regular exerciseUnder test marketingFit-eNce HomeService to provide scientifically evidenced exercise programs and systems supporting regular exerciseat homeUnder test marketingBlueStarDigital therapeutics for adults with diabetesUnder clinical trial preparationWelldocPrecision surgery-guide enabling identification of ureter in hysterectomy and colorectal surgery etc.P-IIIPatientoutcomemaximizationpudexacianiniumchlorideASP5354* The list shows the most advanced stage if the stages are different depending on the region.Updates from the previous announcement (Feb 2022)BlueStar: Entered into clinical trial preparation phase.(cid:52)(cid:14)(cid:19)(cid:21)